Viridian Therapeutics, Inc.
LSE: 0K1R.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen F. Mahoney
- Employees
- 143
- Headquarters
- Waltham, United States
- IPO year
- 2018
- Market cap
- $1.5B
- Website
- https://www.viridiantherapeutics.com
Loading 0K1R…
Loading profile data…Frequently asked questions about 0K1R
What does Viridian Therapeutics, Inc. (0K1R.L) do?
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
Where does 0K1R.L trade?
Viridian Therapeutics, Inc. (0K1R.L) trades on the London Stock Exchange.
What sector is 0K1R.L in?
Viridian Therapeutics, Inc. (0K1R.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Viridian Therapeutics, Inc.?
Stephen F. Mahoney is the chief executive officer of Viridian Therapeutics, Inc. (0K1R.L).
Where is Viridian Therapeutics, Inc. headquartered?
Viridian Therapeutics, Inc. is headquartered in United States.
Does 0K1R.L pay a dividend?
Viridian Therapeutics, Inc. (0K1R.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0K1R.L go public?
Viridian Therapeutics, Inc. (0K1R.L) completed its initial public offering in 2018.